Lucius Larotrectinib – Acheter en ligne
Lucius Larotrectinib – Acheter en ligne
Lucius Larotrectinib – Acheter en ligne

Lucius Larotrectinib – Acheter en ligne

EUR 147.33

2,700+ vendus
Prix promo

Pharmacie physique à Hong Kong, authenticité 100% garantie

Points forts

In 2018, the FDA approved larotrectinib in the United States for tumors driven by NTRK1, NTRK2, or NTRK3 gene fusions. Use only as directed by a physician.

Garanties de service

Expédition transfrontalièrePharmacie agrééeContrôle pharmacienGarantie authenticité

Caractéristiques

Spécification
100mg*30 gelules
Fabricant
Lucius Pharmaceuticals
Expédition
Hong Kong

10000 en stock

Catégorie : Marque :

Informations produit

Nom anglais
Larotrectinib
Nom générique
Larotrectinib

Caractéristiques

Spécification
100mg*30 gelules
Fabricant
Lucius Pharmaceuticals
Expédition
Hong Kong

Détails complets

Indications

Indicated for adults and children with solid tumors harboring an NTRK gene fusion, without a known acquired resistance mutation, when the disease is metastatic, surgery would likely cause severe complications, or no satisfactory alternative treatment remains.

Mécanisme d’action

TRK ， TRKA TRKB TRKC ， TRKA TRKB TRKC IC50 5-11 nM TNK2 100 TRKA TRKB TRKC NTRK1 NTRK2 NTRK3

Pharmacologie

12.1 Mecanisme d action (TRK) ， TRKA TRKB TRKC ， TRKA TRKB TRKC IC50 5-11 nM TNK2 100 TRKA TRKB TRKC NTRK1 NTRK2 NTRK3

Posologie

2.1 NTRK VITRAKVI [ (14)] (MASC) (CMN) ， NTRK ， FDA ， ≥ 1 Recommended dosage:VITRAKVI 100 mg， ， ， ≤ 1 Recommended dosage:

Precautions

5.1 VITRAKVI (CNS) ， VITRAKVI (n=444) ，40.3% CNS ， ， 3.8% 3-4 CNS 11% 6 2 56 ≥ 1% (4.1%) (3.6%) (2.3%) (1.6%) (1.4%) (1.1%)

Interactions médicamenteuses

7.1 CYP3A4 CYP3A4 ， [ (12.3)] CYP3A4 CYP3A4 ， [ Posologie(2.5)] CYP3A4 ， ， [ Posologie(2.5)]

Effets indésirables

Description [ Precautions(5.1)] [ Precautions(5.2)] [ Precautions(5.3)] 6.1 ， ， ， Precautions 444 VITRAKVI ， 62% 6 ，44% ……

Conservation

25 ，2 ， “BAYER” “25 mg” 60 ，NDC 50419-390-01 100 ，0 ， “BAYER” “100 mg” 60 ，NDC 50419-391-01 20°C 25°C 68°F 77°F

Package Insert

Ingredients

11 VITRAKVI C₂₁H₂₄F₂N₆O₆S， 526.51 g/mol， 428.44 g/mol (3S)-N-{5-[(2R)-2-(2,5- )-1- ] [1,5-a] -3- }-3- -1- ，

Indications

Indicated for adults and children with solid tumors harboring an NTRK gene fusion, without a known acquired resistance mutation, when the disease is metastatic, surgery would likely cause severe complications, or no satisfactory alternative treatment remains.

Posologie

2.1 NTRK VITRAKVI [ (14)] (MASC) (CMN) ， NTRK ， FDA ， ≥ 1 Recommended dosage:VITRAKVI 100 mg， ， ， ≤ 1 Recommended dosage:

Effets indésirables

Description [ Precautions(5.1)] [ Precautions(5.2)] [ Precautions(5.3)] 6.1 ， ， ， Precautions 444 VITRAKVI ， 62% 6 ，44% ……

Precautions

5.1 VITRAKVI (CNS) ， VITRAKVI (n=444) ，40.3% CNS ， ， 3.8% 3-4 CNS 11% 6 2 56 ≥ 1% (4.1%) (3.6%) (2.3%) (1.6%) (1.4%) (1.1%)

Use in Pregnancy and Lactation

8.1 ， TRK ， Mecanisme d action[ (12.1)]，VITRAKVI VITRAKVI ， ， ， 100 mg 11 0.7 ， ，

Interactions médicamenteuses

7.1 CYP3A4 CYP3A4 ， [ (12.3)] CYP3A4 CYP3A4 ， [ Posologie(2.5)] CYP3A4 ， ， [ Posologie(2.5)]

Clinical Pharmacology

12 12.1 Mecanisme d action (TRK) ， TRKA TRKB TRKC ， TRKA TRKB TRKC IC50 5-11 nM TNK2 100 TRKA TRKB TRKC NTRK1 NTRK2 NTRK3 TRK ， ，

Clinical Studies

14 VITRAKVI ， NTRK LOXO-TRK-14001 (NCT02122913) SCOUT (NCT02637687) NAVIGATE (NCT02576431) ， ， VITRAKVI 100 mg， 18 VITRAKVI 100 mg/m²， ， 100 mg NTRK

Conservation

25 ，2 ， “BAYER” “25 mg” 60 ，NDC 50419-390-01 100 ，0 ， “BAYER” “100 mg” 60 ，NDC 50419-391-01 20°C 25°C 68°F 77°F

Avis produit (15)

Filtre : Tous les avis
4.8★★★★★
15 avis clients12 achats verifies
+o***e· 3周前
★★★★
+t***3· 1个月前
Achat verifie
★★★★★

Description

Indications

Indicated for adults and children with solid tumors harboring an NTRK gene fusion, without a known acquired resistance mutation, when the disease is metastatic, surgery would likely cause severe complications, or no satisfactory alternative treatment remains.

Mécanisme d’action

TRK ， TRKA TRKB TRKC ， TRKA TRKB TRKC IC50 5-11 nM TNK2 100 TRKA TRKB TRKC NTRK1 NTRK2 NTRK3

Pharmacologie

12.1 Mecanisme d action (TRK) ， TRKA TRKB TRKC ， TRKA TRKB TRKC IC50 5-11 nM TNK2 100 TRKA TRKB TRKC NTRK1 NTRK2 NTRK3

Posologie

2.1 NTRK VITRAKVI [ (14)] (MASC) (CMN) ， NTRK ， FDA ， ≥ 1 Recommended dosage:VITRAKVI 100 mg， ， ， ≤ 1 Recommended dosage:

Precautions

5.1 VITRAKVI (CNS) ， VITRAKVI (n=444) ，40.3% CNS ， ， 3.8% 3-4 CNS 11% 6 2 56 ≥ 1% (4.1%) (3.6%) (2.3%) (1.6%) (1.4%) (1.1%)

Interactions médicamenteuses

7.1 CYP3A4 CYP3A4 ， [ (12.3)] CYP3A4 CYP3A4 ， [ Posologie(2.5)] CYP3A4 ， ， [ Posologie(2.5)]

Effets indésirables

Description [ Precautions(5.1)] [ Precautions(5.2)] [ Precautions(5.3)] 6.1 ， ， ， Precautions 444 VITRAKVI ， 62% 6 ，44% ……

Conservation

25 ，2 ， “BAYER” “25 mg” 60 ，NDC 50419-390-01 100 ，0 ， “BAYER” “100 mg” 60 ，NDC 50419-391-01 20°C 25°C 68°F 77°F